A kinase inhibitor screen reveals MEK1/2 as a novel therapeutic target to antagonize IGF1R-mediated antiestrogen resistance in ERα-positive luminal breast cancer von Wester, L., Venneker, S., Hazenoot, M., Pont, C., Koedoot, E., Timmermans, A.M., Martens, J.W.M., Jansen, M.P.H.M., Kockx, C.E.M., van IJcken, W.F.J., Meerman, J.H.N., Zhang, Y., van de Water, B.

Volltext

A kinase inhibitor screen reveals MEK1/2 as a novel therapeutic target to antagonize IGF1R-mediated antiestrogen resistance in ERα-positive luminal breast cancer von Wester, L., Venneker, S., Hazenoot, M., Pont, C.M., Koedoot, E., Timmermans, A.M., Martens, J.W.M., Jansen, M.P.H.M., Kockx, C.E.M., IJcken, W.F.J. van, Meerman, J.H.N., Zhang, Y., Water, B. van de

Volltext bestellen